Congress Approves Historic $315M for ALS Research

For families touched by ALS, a devastating diagnosis has long meant watching a loved one decline with few treatment options. That reality is starting to change as Congress approved $315 million in federal ALS research funding for 2026, the highest government investment ever for this disease.

ALS, also called Lou Gehrig's disease, affects roughly 30,000 people in the U.S. The disease attacks motor neurons while leaving the mind fully aware, making it particularly cruel for patients and families.

Indu Navar knows this firsthand. It took two years for her husband Peter to get diagnosed as they visited multiple doctors. He died from ALS in 2019, but Navar channeled her grief into action by founding EverythingALS, a nonprofit connecting patients directly with researchers and drug companies.

"We need to be very open about what we are going through so we can actually fix it," Navar said. Her organization now includes nearly two dozen pharmaceutical companies working together to accelerate treatment development.

One of those companies, VectorY Therapeutics, just dosed its first patient in a groundbreaking trial. Their treatment targets TDP-43, a protein problem found in up to 97% of ALS patients that disrupts essential cell functions.

The Ripple Effect

This surge in ALS research momentum reaches far beyond individual patients. The collaboration between patient advocates and drugmakers is solving real problems that have slowed progress for years, like overly strict trial requirements that excluded people who desperately needed access to experimental treatments.

EverythingALS is also working with the FDA to approve new ways of measuring whether treatments actually help, like tracking improvements in speech. Meanwhile, their partnership with ALSUntangled helps patients separate real science from false hope when evaluating alternative therapies.

Dr. Olga Uspenskaya, Chief Medical Officer at VectorY, sees genuine reasons for optimism. "If you can slow or halt ALS even modestly, you're changing the trajectory of life for almost every ALS patient," she said.

Advances in genetics and biomarker technology mean scientists can now detect the disease earlier and design smarter, more targeted trials. After years of setbacks and withdrawn treatments, multiple promising therapies are moving through development pipelines simultaneously.

The timing couldn't be better, arriving during February's Rare Disease Month as a reminder that progress is possible even for the most challenging conditions. For families like Navar's, this unprecedented investment and scientific momentum represent something they've desperately needed: hope backed by real action.